Skip to main content

Advertisement

SpringerLink
Log in

Comment on “Cardiovascular risk stratification and appropriate use of statins in patients with systemic lupus erythematosus according to different strategies”

  • Letter to the Editor
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Masson W, Rossi E, Mora-Crespo LM, Cornejo-Pena G, Pessio C, Gago M et al (2019) Cardiovascular risk stratification and appropriate use of statins in patients with systemic lupus erythematosus according to different strategies. Clin Rheumatol:1–8. https://doi.org/10.1007/s10067-019-04856-z

  2. Icli A, Cure E, Cure MC, Uslu AU, Balta S, Mikhailidis DP, Ozturk C, Arslan S, Sakız D, Sahin M, Kucuk A (2016) Endocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosus. Angiology 67:749–755

    Article  CAS  Google Scholar 

  3. Uslu AU, Kucuk A, Icli A, Cure E, Sakiz D, Arslan S et al (2017) Plasma atherogenic index is an independent indicator of subclinical atherosclerosis in systemic lupus erythematosus. Eurasian J Med 49:193–197

    Article  CAS  Google Scholar 

  4. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group (2013) KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Inter 3:259–305

    Article  Google Scholar 

  5. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R, SHARP Investigators (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet 377:2181–2192

    Article  CAS  Google Scholar 

  6. Roy R, Ajithan A, Joseph A, Mateti UV, K S (2019) Statin-induced new onset of diabetes in dyslipidemic patients: a retrospective study. Postgrad Med. https://doi.org/10.1080/00325481.2019.1643636

    Article  Google Scholar 

  7. Sinicato NA, Postal M, de Oliveira PK, Rittner L, Marini R, Appenzeller S (2017) Prevalence and features of metabolic syndrome in childhood-onset systemic lupus erythematosus. Clin Rheumatol 36:1527–1535

    Article  Google Scholar 

  8. Cho Y, Lee H, Park HK, Choe EY, Wang HJ, Kim RH et al (2019) Differential diabetogenic effect of pitavastatin and rosuvastatin, in vitro and in vivo. J Atheroscler Thromb. https://doi.org/10.5551/jat.50039

  9. Chen LW, Lin CS, Tsai MC, Shih SF, Lim ZW, Chen SJ et al (2019) Pitavastatin exerts potent anti-inflammatory and immunomodulatory effects via the suppression of AP-1 signal transduction in human T cells. Int J Mol Sci. https://doi.org/10.3390/ijms20143534

    Article  CAS  Google Scholar 

  10. Chan P, Shao L, Tomlinson B, Zhang Y, Liu ZM (2019) An evaluation of pitavastatin for the treatment of hypercholesterolemia. Expert Opin Pharmacother 20:103–113

    Article  CAS  Google Scholar 

  11. https://www.drugs.com/drug-interactions/pitavastatin,nikita.html

  12. Hartman O, Kovanen PT, Lehtonen J, Eklund KK, Sinisalo J (2017) Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. Eur Heart J Cardiovasc Pharmacother 3:92–97

    PubMed  Google Scholar 

  13. Pareek A, Yeole PG, Tenpe CR, Chandurkar N, Payghan R (2009) Effect of atorvastatin and hydroxychloroquine combination on blood glucose in alloxan-induced diabetic rats. Indian J Pharmacol 41:125–128

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Erkan Cure Department of Internal Medicine, Ota&Jinemed Hospital, Muradiye Mahallesi Nuzhetiye Cad, Deryadil Sokagi No:1, 34357, Istanbul, Besiktas, Turkey

    Erkan Cure

  2. Department of Biochemistry, Private Practice, Istanbul, Turkey

    Medine Cumhur Cure

Authors
  1. Erkan Cure
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Medine Cumhur Cure
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erkan Cure.

Ethics declarations

Disclosures

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cure, E., Cumhur Cure, M. Comment on “Cardiovascular risk stratification and appropriate use of statins in patients with systemic lupus erythematosus according to different strategies”. Clin Rheumatol 39, 615–616 (2020). https://doi.org/10.1007/s10067-019-04897-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-019-04897-4

Search

Navigation